射频消融联合系统化疗治疗不可切除或术后复发肝内胆管癌的效果和安全性

孙巍; 丁晓燕; 陈京龙; 李文东; 郭晓笛; 申燕军; 孙莎莎; 滕颖; 刘晓民; 魏建莹

doi:10.3969/j.issn.1001-5256.2018.08.025

射频消融联合系统化疗治疗不可切除或术后复发肝内胆管癌的效果和安全性

DOI: 10.3969/j.issn.1001-5256.2018.08.025

首都医科大学附属北京地坛医院肿瘤科北京市医院管理局重点医学专业发展计划-肝炎专业首都医科大学附属北京地坛医院临床数据与样本资源库

基金项目:

首都临床特色应用研究与成果推广(Z161100000516141)；

详细信息

中图分类号: R735.8
计量
- 文章访问数: 2230
- HTML全文浏览量: 17
- PDF下载量: 367
- 被引次数: 0
出版历程
- 收稿日期: 2018-03-01
- 出版日期: 2018-08-20

Clinical effect and safety of radiofrequency ablation combined with systemic chemotherapy in treatment of unresectable or postoperative recurrent intrahepatic cholangiocellular carcinoma

Department of Oncology, Beijing Ditan Hospital, Capital Medical University, Beijing, Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support, Biobank of Clinical Resources of Beijing Ditan Hospital, Captial Medical University

Research funding:

摘要

摘要: 目的回顾性分析经皮射频消融治疗（RFA）联合静脉化疗治疗不可切除或术后复发肝内胆管癌的效果及安全性。方法选取2011年1月-2016年12月首都医科大学附属北京地坛医院诊治的不可切除或术后复发肝内胆管癌患者。所有患者首先行RFA治疗。RFA治疗均在CT引导下完成。术后1周开始进行全身化疗,方案为吉西他滨联合顺铂（具体为吉西他滨1000 mg/m2第1、8天及顺铂25 mg/m2第1、8天,共6个周期）。主要观察指标为完全消融率、客观缓解率、至疾病进展时间、肿瘤局部进展率、生存时间和安全性。结果 24例患者中共包含45个病灶,均完成RFA治疗及化疗。客观缓解率为79.2%,术后1个月肿瘤完全消融率为86.7%（39/45）。术后随访1167个月,至随访结束肿瘤局部进展率为20.0%（9/45）;中位至疾病进展时间为13.0个月;中位生存时间为28.6个月,1、2、3年生存率分别为87.3%、69.3%、32.6%。至随访结束主要副反应为血液学毒性及转氨酶升高,无手术严重并发症发生。结论 RFA联合系统化疗治疗不可切除或术后复发肝内胆管癌是一种安全可行的方案。
- 肝肿瘤 /
- 导管消融术 /
- 药物疗法,联合 /
- 治疗结果
Abstract: Objective To investigate the clinical effect and safety of percutaneous radiofrequency ablation ( RFA) combined with systemic chemotherapy in the treatment of unresectable or postoperative recurrent intrahepatic cholangiocellular carcinoma. Methods The patients with unresectable or postoperative recurrent cholangiocellular carcinoma who were treated from January 2011 to December 2016 were enrolled. All patients underwent CT-guided RFA, followed by systemic chemotherapy since one week after surgery, with the regimen of gemcitabine given concurrently with cisplatin ( gemcitabine 1000 mg/m2 combined with cisplatin 25 mg/m2 on days 1 and 8, for 6 cycles in total) . Treatment outcome and safety were observed. Results There were 45 lesions in total, and RFA and chemotherapy were performed for all lesions. The overall objective response rate was 79. 2%. The complete ablation rate of the lesions at one month after surgery was 86. 7% ( 39/45) . The patients were followed up for 11-67 months after surgery, and at the end of follow-up, the rate of local progression was20. 0% ( 9/45) . The median time to progression was 13. 0 months, the median survival time was 28. 6 months, and the 1-, 2-, and 3-yaer survival rates were 87. 3%, 69. 3%, and 32. 6%, respectively. Major side effects included hematological toxicity and elevated aminotransferases, and there were no serious adverse events associated with RFA. Conclusion RFA combined with systemic chemotherapy is a safe and feasible regimen for unresectable or postoperative recurrent intrahepatic cholangiocellular carcinoma.
- liver neoplasms /
- catheter ablation /
- drug therapy, combination /
- treatment outcome

HTML全文

参考文献(22)

[1]SHAIB Y, EL-SERAG HB.The epidemiology of cholangiocarcinoma[J].Semin Liver Dis, 2004, 24 (2) :115-125.

[2]BLECHACZ B, GORES GJ.Cholangiocarcinoma:Advances in pathogenesis, diagnosis, and treatment[J].Hepatology, 2008, 4 (1) :308-321.

[3]PADIA SA.Intrahepatic cholangiocarcinoma[J].Tech Vasc Interv Radiol, 2015, 18 (4) :227-235.

[4]SPOLVERATO G, KIM Y, ALEXANDRESCU S, et al.Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection[J].Ann Surg Oncol, 2016, 23 (1) :235-243.

[5]LENCIONI R, CROCETTI L.Image-guided ablation for hepatocellular carcinoma[J].Recent Results Cancer Res, 2013, 190:181-194.

[6]ZIEMLEWICZ TJ, WELLS SA, LUBNER MG, et al.Hepatic tumor ablation[J].Surg Clin North Am, 2016, 96 (2) :315-339.

[7]SIMO KA, HALPIN LE, MCBRIER NM, et al.Multimodality treatment of intrahepatic cholangiocarcinoma:A review[J].J Surg Oncol, 2016, 113 (1) :62-83.

[8]HAN K, KO HK, KIM KW, et al.Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma:Systematic review and meta-analysis[J].J Vasc Interv Radiol, 2015, 26 (7) :943-948.

[9]VALLE J, WASAN H, PALMER DH, et al.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J].N Engl J Med, 2010, 362 (14) :1273-1281.

[10]BRIDGEWATER J, GALLE PR, KHAN SA, et al.Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J].J Hepatol, 2014, 60 (6) :1268-1289.

[11]SØRENSEN JB, KLEE M, PALSHOF T, et al.Performance status assessment in cancer patients.An inter-observer variability study[J].Br J Cancer, 1993, 67 (4) :773-775.

[12]BRUIX J, SHERMAN M, LLOVET JM, et al.Clinical management of hepatocellular carcinoma.Conclusions of the Barcelona-2000 EASL conference.European Association for the Study of the Liver[J].J Hepatol, 2001, 35 (3) :421-430.

[13]EISENHAUER EA, THERASSE P, BOGAERTS J, et al.New response evaluation criteria in solid tumours:Revised RECIST guideline (version 1.1) [J].Eur J Cancer, 2009, 45 (2) :228-247.

[14]GOLDBERG SN, CHARBONEAU JW, DODD GD, et al.Imageguided tumor ablation:Proposal for standardization of terms and reporting criteria[J].Radiology, 2003, 228 (2) :335-345.

[15]AMIN MA, GREENE FL, EDGE S, et al.AJCC Cancer Staging Manual[M].8th ed.New York:Springer, 2017.

[16]JARNAGIN WR, SHOUPM.Surgical management of cholangiocarcinoma[J].Semin Liver Dis, 2004, 24 (2) :189-199.

[17]BOEHM LM, JAYAKRISHNAN TT, MIURA JT, et al.Comparative effective-ness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma[J].J Surg Oncol, 2015, 111 (2) :213-220.

[18]BUTROS SR, SHENOY-BHANGLE A, MUELLER PR, et al.Radiofrequency ablation of intrahepatic cholangiocarcinoma:Feasability, local tumor control, and long-term outcome[J].Clin Imaging, 2014, 38 (4) :490-494.

[19]KIM JH, WON HJ, SHIN YM, et al.Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma[J].AJR Am J Roentgenol, 2011, 196 (2) :205-209.

[20]YANG GW, ZHAO Q, QIAN S, et al.Percutaneous microwave ablation combined with simultaneous transarterial chemoembolization for the treatment of advanced intrahepatic cholangiocarcinoma[J].Onco Targets Ther, 2015, 8:1245-1250.

[21]SEIDENSTICKER R, SEIDENSTICKER M, DOEGEN K, et al.Extensive use of interventional therapies improves survival in unresectable or recurrent intrahepatic cholangiocarcinoma[J].Gastroenterol Res Pract, 2016, 2016:8732521.

[22]CARRAFIELLO G, LAGANA D, COTTA E, et al.Radiofrequency ablation of intrahepatic cholangiocarcinoma:Preliminary experience[J].Cardiovasc Intervent Radiol, 2010, 33 (7) :835-839.

施引文献

资源附件(0)

访问统计